Singapore-based medical technology Biolidics Limited is tapping the SGX Catalist market by issuing 27.5 million placement shares at S$0.28 apiece to raise approximately S$7.7 million ($5.6 million) in gross proceeds from the IPO.
The IPO offer closes on December 17, 2018, and listing will take place on December 19, 2018. United Overseas Bank (UOB) Limited is managing the issue.
